Medically reviewed by Andrew Greenberg, MD Bull’s-eye maculopathy is an eye problem that affects the macula, the part of the ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ... human CNTF -- to the affected eye via a surgical intravitreal ...

March 7, 2025 – The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only ...

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia type 2 (MacTel), a rare eye disease leading to progressive and ...

The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...

The tiny eye insert delivers cell therapy to slow ... has approved its “encapsulated cell therapy” implant for Macular Telangiectasia Type 2, a disease known as MacTel. MacTel is a rare ...

The FDA last week approved (PDF) Neurotech’s cell therapy implant revakinagene taroretcel to treat the vision-robbing neurodegenerative disease macular telangiectasia (MacTel) type 2.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2 ... protein administration for chronic eye disease following surgical implantation.